Menu hamburgerclose
About us


Our mission is to make a novel therapeutic approach a reality in PD – an area where clinicians and patients saw disappointingly little innovation in decades.

Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial in 2022.

The Company is lead by a management team that combines extensive expertise in the renal business, in financing and Venture Capital, as well as in nephrology and clinical development.


Key Milestones

2019         Participation in EU Horizon 2020 project Improve-PD

2017         FDA grants Orphan Drug Designation to PDprotec®

2017         Results of Phase II trial of PDprotec®: Outstanding safety and efficacy profile

2016/17    Series A2 Financing

2016         Zytoprotec opens laboratory for biomarker research in PD 

2015         Double-blinded, placebo-controlled Phase II trial of PDprotec® initiated

2013         Series A Financing

2012         EPO grants patent for PDprotec®

2012         Phase I/II trial with PDprotec® completed

2011         First financing with private investors

2007         Zytoprotec founded